SavedAdd your journal

Journals / Arşiv Kaynak Tarama Dergisi / 2017 / Cilt: 26 - Sayı: 1

Pharmacological Treatment in Fibromyalgia

Fibromiyaljide Farmakolojik Tedavi

Ayhan AŞKIN
Ayten ÖZKAN
Pages
124–141
Publication Date
2022-10-11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Further evidence-based trials using complementary treatments are needed

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fibromyalgia is a multisystem disorder characterized by widespread pain.
📊
Key Findings & Data:Although there is no known cure for fibromyalgia, multidisciplinary team efforts using combined treatment approaches, including patient education, aerobic exercise, cognitive behavioral therapy, and pharmacologic therapies (serotonin norepinephrine reuptake inhibitors [eg, duloxetine, milnacipran] and alpha 2-delta receptor ligands [eg, pregabalin]) may improve symptoms as well as function of patients with fibromyalgia.
💡
Conclusion & Impact:Further evidence-based trials using complementary treatments are needed
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Fibromyalgia is a multisystem disorder characterized by widespread pain. Although there is no known cure for fibromyalgia, multidisciplinary team efforts using combined treatment approaches, including patient education, aerobic exercise, cognitive behavioral therapy, and pharmacologic therapies (serotonin norepinephrine reuptake inhibitors [eg, duloxetine, milnacipran] and alpha 2-delta receptor ligands [eg, pregabalin]) may improve symptoms as well as function of patients with fibromyalgia. Some success has been shown with dopamine agonists (pramipexole), tramadol, other opioids and cannabinoids (nabilone). Further evidence-based trials using complementary treatments are needed

Özet

Fibromiyalji kronik yaygın ag?rı ile karakterize multisistemik bir hastalıktır. Tedavisinde kür olmamakla birlikte hasta eğitimi, aerobik egzersizler, kognitif davranışsal terapi, farmakolojik tedavilerin (serotonin noradrenalin geri alım inhibitörleri [Ör,duloksetin,milnasipran] ve alfa 2-delta reseptör ligandı [Ör,pregabalin]) kombine multidisipliner ekip yaklaşımı ile kullanımı hastalarda semptomların ve özellikle fonksiyonun düzelmesine yardımcı olabilir. Dopamin agonistleri (pramipeksol), tramadol, diğer opioidler ve kannabinoidlerin (nabilon) ile de bazı başarılı sonuçlar gösterilmiştir. Tamamlayıcı tedaviler kullanarak daha fazla kanıta dayalı çalışmalara ihtiyaç vardır

🔖

Cite This Article

AŞKIN, A., ÖZKAN, A. (2022). Pharmacological Treatment in Fibromyalgia. Arşiv Kaynak Tarama Dergisi, Cilt: 26 - Sayı: 1, 124–141. https://ajindex.com/articles/449235

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Bhusal S, Diomampo S, Magrey MN. Clinical utility, safety, and efficacy of pregabalin in the treatment of fibromyalgia. Drug HealthcPatient Saf. 2016;8:13-23
  2. Wolfe F, Ross K, Anderson J, Russell IJ. Aspects of fibromyalgia in the general population: sex, pain threshold, and fibromyalgia symptoms. J Rheumatol.1995;22:151-6
  3. Smith HS, Harris R, Clauw D. Fibromyalgia: an afferent processing disorder leading to a complex pain generalized syndrome. Pain Physician. 2011;14:217-45
  4. Häuser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review.Eur J Pain. 2010;14:5-10
  5. Häuser W, Walitt B, Fitzcharles MA, Sommer C. Review of pharmacological therapies in fibromyalgia syndrome. Arthritis Res Ther. 2014;16:201
  6. Verkamp EK, Flowers SR, Lynch-Jordan AM, Taylor J, Ting TV, Kashikar-Zuck S. A survey of conventional and complementary therapies used by youth with juvenile-onset fibromyalgia. Pain Manag Nurs. 2013;14:244-50
  7. Marschall U, Arnold B, Häuser W. Treatment and healthcare costs of fibromyalgia syndrome in Germany: analysis of the data of the Barmer health insurance (BEK) from 2008-2009. Schmerz. 2011;25:406-10
  8. Legangneux E, Mora JJ, Spreux-Varoquaux O, Thorin I, Herrou M, Alvado G, et al. Cerebrospinal fluid biogenic amine metabolites, plasma-rich platelet serotonin and [3H] imipramine reuptake in the primary fibromyalgia syndrome. Rheumatology (Oxford). 2001;40:290-6
  9. Häuser W, Wolfe F, Tölle T, Uçeyler N, Sommer C. The role of antidepressants in the management of fibromyalgia syndrome: a systematic review and meta-analysis. CNS Drugs. 2012;26:297-307
  10. Lange M, Petermann F. Influence of depression on fibromyalgia: a systematic review. Schmerz. 2010;24:326-33
  11. Häuser W, Galek A, Erbslöh-Möller B, Köllner V, Kühn-Becker H, Langhorst J et al. Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome. Pain. 2013;154:1216-23
  12. Uğurlu H, Arasıl T. Fiziksel Tıp ve Rehabilitasyonda Yeni Ufuklar, Fibromiyalji. Ankara, Güneş Kitabevi.2012
  13. Lawson K. Treatment options and patient perspectives in the management of fibromyalgia: future trends. Neuropsychiatr Dis Treat. 2008;4:1059-71
  14. Goldenberg DL. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain. Best Pract Res Clin Rheumatol. 2007;21:499-511
  15. Millea PJ, Holloway RL. Treating fibrom